Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Cyclophosphamide Induction Therapy for Adult HLH
NCT05936086Recruiting
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclophosphamide in hemophagocytic lymphohistiocytosis (HLH) (2 arms). Primary endpoints: Complete Response Rate at 30 days and Near Complete Response Rate at 30 days. Started Apr 2023; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05936086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05936086.